“Strongly consider an SGLT2-inhibitor in most T2DM patients” Presented ByProf. Deepak Bhatt, Brigham and Women’s Hospital, USA TrialPhase 3, SOLOIST-WHF; SCORED ConferenceAHA 2020 18 February, 2021 10:14